May 5, 2008
Oncothyreon Files Investigational New Drug Application For PX-866...
“PX-866 is a potent inhibitor of phosphatidylinositol-3-kinase that has demonstrated preclinical anti-tumor activity in models of human ovarian cancer, lung cancer and intracranial glioblastoma”
Oncothyreon Inc. recently announced that it has filed an investigational new drug application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for ... via Pharmaceutical Online
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
